VKTX

VKTX

USD

Viking Therapeutics Inc. Common Stock

$34.630-2.110 (-5.743%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$36.740

Máximo

$38.000

Mínimo

$34.615

Volume

3.77M

Fundamentos da empresa

Capitalização de mercado

3.9B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

6.60M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $18.92Atual $34.630Máximo $70.41

Notícias relacionadas

Reuters

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera has become the obesity drug market's hottest ticket.

Ver mais
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Analyst Upgrades

Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106

Canaccord Genuity analyst Edward Nash initiates coverage on Viking Therapeutics with a Buy rating and announces Price Target of $106.

Ver mais
Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106
Analyst Upgrades

JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics with a Overweight and lowers the price target from $80 to $75.

Ver mais
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75
Analyst Upgrades

Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102

Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics with a Overweight and raises the price target from $98 to $102.

Ver mais
Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102
PR Newswire

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

Ver mais
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...